ScholarIQanswers from OpenAlex & ORCID
David R. Freyer
ResearcherPublications, citations & collaboration network
David R. Freyer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David R. Freyer have?
ScholarIQindexed works
David R. Freyer has 387 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David R. Freyer have?
ScholarIQcitation count
David R. Freyer has 9,769 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David R. Freyer?
ScholarIQh-index
David R. Freyer has an h-index of 54 in OpenAlex.
What is the i10-index of David R. Freyer?
ScholarIQi10-index
David R. Freyer has an i10-index of 148 in OpenAlex.
What is the ORCID of David R. Freyer?
ScholarIQorcid
The ORCID for David R. Freyer is on the source record.
What is the OpenAlex record for David R. Freyer?
ScholarIQopenalex
The OpenAlex for David R. Freyer is on the source record.
What are the most-cited papers on David R. Freyer?
ScholarIQmost cited works
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Joann L. Ater, Tianni Zhou, Emiko J. Holmes, Claire Mazewski, Timothy N. Booth, David R. Freyer, Ken H. Lazarus, Roger J. Packer, Michael D. Prados, Richard Sposto, Gilbert Vézina, Jeffrey H. Wisoff, Ian F. Pollack
Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale
Penelope Brock, Kristin R. Knight, David R. Freyer, Kathleen C. M. Campbell, Peter S. Steyger, Brian W. Blakley, Shahrad R. Rassekh, Kay W. Chang, Brian J. Fligor, Kaukab Rajput, Michael Sullivan, Edward A. Neuwelt
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study
Eugene Suh, Kayla Stratton, Wendy M. Leisenring, Paul C. Nathan, Jennifer S. Ford, David R. Freyer, Jennifer L. McNeer, Wendy Stock, Marilyn Stovall, Kevin R. Krull, Charles A. Sklar, Joseph P. Neglia, Gregory T. Armstrong, Kevin C. Oeffinger, Leslie L. Robison, Tara O. Henderson
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group
Nita L. Seibel, Peter G. Steinherz, Harland N. Sather, James B. Nachman, Cynthia DeLaat, Lawrence J. Ettinger, David R. Freyer, Leonard A. Mattano, Caroline A. Hastings, Charles M. Rubin, Kathy Bertolone, Janet Franklin, Nyla A. Heerema, Torrey L. Mitchell, Allan F. Pyesmany, Mei La, Cheryl Edens, Paul S. Gaynon
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
David R. Freyer, Rosemarie Kennedy, Bruce Bostrom, Gloria Kohut, Louis P. Dehner